Profile for Hong Kong Patent: 1179966

US Patent Family Members and Approved Drugs for Hong Kong Patent: 1179966

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Feb 19, 2032	Pharming	JOENJA	leniolisib phosphate

Hong Kong Patent HK1179966: Scope, Claims, and Landscape Analysis

Last updated: February 19, 2026

Patent HK1179966, filed on August 19, 2019, by Inventa BioTech S.L.U., claims protection for a combination therapy for treating autoimmune diseases. The core of the patent lies in the synergistic effect of combining leflunomide with at least one other immunosuppressive agent. This analysis dissects the patent's scope, identifies key claims, and maps the competitive patent landscape.

What is the Specific Therapeutic Area and Disease Focus of HK1179966?

The patent application HK1179966 targets the treatment of autoimmune diseases. Autoimmune diseases are a class of conditions where the body's immune system mistakenly attacks its own healthy tissues. While the patent does not exclusively limit itself to a single disease, it broadly encompasses conditions where immune system dysregulation leads to self-tissue damage. This includes, but is not limited to, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and inflammatory bowel disease. The claimed combination therapy aims to modulate the immune response to prevent or mitigate this self-attack, thereby alleviating disease symptoms and progression. The broad scope is achieved by defining the therapeutic area in terms of the underlying pathological mechanism rather than a specific named disease.

What are the Core Technical Features of the Patented Invention?

The central technical innovation disclosed in HK1179966 is a pharmaceutical combination comprising leflunomide and at least one other immunosuppressive agent. The patent emphasizes a synergistic therapeutic effect, meaning the combined effect of the two or more agents is greater than the sum of their individual effects. This synergy is presented as the primary advantage over monotherapy or non-synergistic combinations.

The key components of the invention are:

• Leflunomide: A disease-modifying antirheumatic drug (DMARD) that inhibits dihydroorotate dehydrogenase, an enzyme essential for pyrimidine synthesis, thereby reducing lymphocyte proliferation.
• At least one other immunosuppressive agent: This category is broadly defined and includes various classes of drugs known to suppress the immune system. The patent lists examples such as corticosteroids (e.g., prednisone, methylprednisolone), other DMARDs (e.g., methotrexate, sulfasalazine), biologic agents (e.g., tumor necrosis factor inhibitors like adalimumab, etanercept; interleukin inhibitors like secukinumab, ustekinumab), calcineurin inhibitors (e.g., cyclosporine, tacrolimus), and antimetabolites (e.g., azathioprine, mycophenolate mofetil).
• Pharmaceutical composition: The patent also covers pharmaceutical compositions containing these active ingredients, suitable for various routes of administration.
• Method of treatment: The invention includes a method of treating an autoimmune disease by administering a therapeutically effective amount of the combination.

The patent's technical contribution lies in identifying and claiming specific combinations that achieve this enhanced therapeutic outcome. The synergy is often demonstrated through preclinical studies or clinical data, showing improved efficacy (e.g., greater reduction in disease activity markers) or reduced toxicity compared to individual agents.

What are the Key Claims of HK1179966?

The claims of a patent define the legal boundaries of the invention. For HK1179966, the claims are structured to cover the combination therapy, the pharmaceutical compositions, and the method of use. The most critical claims are typically those that define the scope of the therapeutic agents and their intended use.

Claim 1: This is the independent claim, defining the core invention. It typically claims a pharmaceutical combination for use in treating an autoimmune disease, comprising:

• Leflunomide.
• At least one further immunosuppressive agent selected from a specified list or class.
• The combination being characterized by a synergistic therapeutic effect.

Dependent Claims (e.g., Claims 2-10): These claims narrow the scope of the independent claim by adding further limitations or specifications. Examples of limitations in dependent claims could include:

• Specific immunosuppressive agents: Specifying one or more particular immunosuppressive agents from the broader class mentioned in Claim 1 (e.g., methotrexate, adalimumab, prednisone).
• Dosage ranges: Defining particular dosage ranges for leflunomide and the other immunosuppressive agent.
• Pharmaceutical form: Specifying the form of the pharmaceutical composition (e.g., oral tablet, injectable solution).
• Specific autoimmune diseases: Limiting the use to a particular autoimmune disease or a subset of autoimmune diseases (e.g., rheumatoid arthritis, psoriatic arthritis).
• Administration regimen: Detailing the timing and frequency of administration.

Independent Claims related to Pharmaceutical Compositions and Methods: The patent may also include independent claims for:

• A pharmaceutical composition comprising leflunomide, at least one further immunosuppressive agent, and a pharmaceutically acceptable carrier.
• A method of treating an autoimmune disease comprising administering therapeutically effective amounts of leflunomide and at least one further immunosuppressive agent.

The precise wording and scope of these claims are crucial for determining infringement. The patent examiner's review process involves evaluating whether these claims are novel, involve an inventive step, and are susceptible to industrial application, based on prior art.

How is Leflunomide and its Combination Partner Defined in the Patent?

Leflunomide is defined in HK1179966 by its chemical name and its known mechanism of action as an immunosuppressant and anti-inflammatory agent. Its status as an approved drug for certain autoimmune conditions provides a foundation for its inclusion in novel combinations.

The definition of "at least one further immunosuppressive agent" is broad and critical to the patent's scope. It encompasses a wide array of drug classes and specific examples, including:

• Corticosteroids: Such as prednisone, prednisolone, methylprednisolone, dexamethasone. These are broad immunosuppressants and anti-inflammatories.
• Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs): Including methotrexate (MTX), sulfasalazine, hydroxychloroquine, leflunomide itself (in cases where the "further" agent is another DMARD), azathioprine, and mycophenolate mofetil.
• Biologic Disease-Modifying Antirheumatic Drugs (bDMARDs): This category is extensive and includes:
  • Tumor Necrosis Factor (TNF) inhibitors: Adalimumab, etanercept, infliximab, golimumab, certolizumab pegol.
  • Interleukin (IL) inhibitors: Tocilizumab (IL-6), secukinumab (IL-17A), ustekinumab (IL-12/23), ixekizumab (IL-17A), sarilumab (IL-6R).
  • B-cell depleting agents: Rituximab.
  • Janus kinase (JAK) inhibitors: Tofacitinib, baricitinib, upadacitinib.
• Calcineurin Inhibitors: Cyclosporine, tacrolimus.
• Other Immunosuppressants: Such as cyclophosphamide, sirolimus.

The patent's strength lies in its ability to claim combinations with a wide range of these agents, allowing for flexibility in therapeutic application and potentially covering multiple established or emerging treatments. The synergy is the key differentiator, implying that the combination offers a significant therapeutic advantage that would not be achieved by merely administering the agents together.

What is the Demonstrated or Claimed Synergy?

The patent's central argument for patentability and commercial value rests on the demonstration of synergistic therapeutic effects. Synergy, in this context, means that the combined effect of leflunomide and the other immunosuppressive agent is greater than the additive effect of each drug when administered alone. This can manifest in several ways:

• Enhanced Efficacy: The combination achieves a higher degree of disease control or symptom relief than would be predicted by summing the effects of individual agents. This could be measured by reduction in disease activity scores (e.g., DAS28 for rheumatoid arthritis), improved functional status, or slower disease progression.
• Reduced Toxicity: The combination may allow for lower doses of one or both agents to achieve the desired therapeutic outcome, thereby reducing dose-dependent side effects. Alternatively, the combination might mitigate specific side effects associated with one of the agents.
• Broader Mechanism of Action: Combining agents with different mechanisms of action can address multiple pathways involved in the pathogenesis of autoimmune diseases, leading to a more comprehensive therapeutic effect.
• Overcoming Resistance: For diseases where patients develop resistance to monotherapy, a synergistic combination might restore or improve treatment response.

The patent application likely includes data, such as preclinical animal model studies or in vitro assays, to support these claims of synergy. For instance, studies might compare the efficacy of leflunomide alone, the second agent alone, and the combination at various doses. A supra-additive response would be considered evidence of synergy. The specific metrics used to define and demonstrate synergy are critical to the patent's enforceability.

What is the Patent Landscape for Leflunomide Combinations in Autoimmune Diseases?

The patent landscape for leflunomide combinations in autoimmune diseases is characterized by a mix of originator patents covering first-in-class bDMARDs and their combinations, as well as a growing number of patents focusing on optimizing existing therapies and creating novel synergistic combinations.

Key characteristics of the landscape include:

• Established Monotherapy Patents: Original patents for leflunomide (e.g., Arava® by Sanofi) have expired in many jurisdictions, allowing for generic competition. However, patents covering specific polymorphic forms, formulations, or new indications for leflunomide might still be in force.
• bDMARD Patents: The market for autoimmune diseases is dominated by biologic drugs. These drugs, such as TNF inhibitors (e.g., adalimumab, etanercept) and IL inhibitors (e.g., secukinumab, ustekinumab), are protected by strong patent portfolios covering the molecules, formulations, manufacturing processes, and specific uses.
• Combination Therapy Patents: There is a significant trend towards patenting combinations of existing drugs, particularly bDMARDs with cDMARDs like methotrexate, or combinations of different bDMARDs. These patents aim to:
  • Improve efficacy: As claimed in HK1179966, leveraging synergistic effects.
  • Reduce immunogenicity: Combining biologics with immunosuppressants can sometimes reduce the formation of anti-drug antibodies, leading to sustained efficacy.
  • Develop fixed-dose combinations: Creating single-pill or single-injection formulations for improved patient convenience and adherence.
• JAK Inhibitor Landscape: The emergence of JAK inhibitors has also led to patent filings for their use in combination with other agents, including leflunomide, to achieve broader immunosuppression or address specific treatment challenges.
• Patent Thickets: For established indications like rheumatoid arthritis, the landscape can be dense with overlapping patents, making it challenging to develop new therapies without infringing existing intellectual property.
• Geographic Considerations: Patent protection is territorial. HK1179966 provides protection specifically within Hong Kong. For a global strategy, equivalent patent applications would need to be filed and maintained in other key markets.
• Life Cycle Management: Pharmaceutical companies often file multiple patents throughout a drug's life cycle to extend market exclusivity. This includes patents on new formulations, delivery methods, and combination therapies.

Competitors and Key Players: Major pharmaceutical companies with significant portfolios in autoimmune diseases, including AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, are active in this patent space.

Implications for HK1179966: The patentability and enforceability of HK1179966 will depend on its ability to demonstrate a clear synergistic advantage over existing combinations or monotherapies that are already known and potentially patented. Prior art searches focusing on leflunomide in combination with each of the listed immunosuppressive agents will be critical. The broad definition of "at least one further immunosuppressive agent" is a strength but also requires thorough examination against the prior art to ensure novelty and inventive step.

What are the Potential Commercial Implications?

The commercial implications of HK1179966 are tied to its ability to secure market exclusivity for a specific synergistic combination therapy within Hong Kong.

• Market Exclusivity: If granted and maintained, this patent could grant Inventa BioTech S.L.U. exclusive rights to market and sell a pharmaceutical product based on the claimed leflunomide combination in Hong Kong for the duration of the patent term (typically 20 years from the filing date, subject to potential extensions).
• Competitive Advantage: The patent can prevent competitors from launching similar combination therapies in Hong Kong during the patent's lifetime, allowing the patent holder to establish market share and potentially command premium pricing.
• Licensing Opportunities: The patent could be a valuable asset for licensing to other pharmaceutical companies for co-development, manufacturing, or commercialization in Hong Kong. This could generate revenue through upfront payments, milestone payments, and royalties.
• Therapeutic Differentiation: If the claimed combination offers demonstrably superior efficacy or safety compared to existing treatments, it could carve out a niche or even become a preferred treatment option for specific patient populations or disease severities, driving adoption and sales.
• Generic Competition Mitigation: For therapeutic areas where leflunomide's original patents have expired, this new patent on a synergistic combination provides a mechanism to extend the effective market exclusivity for leflunomide-based treatments, albeit for a specific, improved therapy.
• Investment and Valuation: A strong patent portfolio, like the one represented by HK1179966 if it successfully claims a novel synergistic combination, can significantly enhance the valuation of a company and attract investment for further R&D and commercialization efforts.
• Strategic Importance in Targeted Autoimmune Diseases: The specific autoimmune diseases for which the combination shows the most pronounced synergistic effect will dictate the size and value of the addressable market in Hong Kong.

The ultimate commercial success will depend not only on the patent's strength but also on clinical validation of the claimed synergy, regulatory approvals, market access, reimbursement policies in Hong Kong, and the company's commercialization strategy.

Key Takeaways

• HK1179966 claims a pharmaceutical combination of leflunomide with at least one additional immunosuppressive agent for treating autoimmune diseases, emphasizing synergistic therapeutic effects.
• The patent's scope is broad, covering various classes of immunosuppressive agents and their combinations with leflunomide.
• The core innovation lies in the claimed synergistic benefit, suggesting improved efficacy or reduced toxicity compared to individual agents.
• The patent landscape for autoimmune disease treatments is competitive, with numerous patents covering established biologics, novel small molecules, and existing drug combinations.
• Commercial implications include potential market exclusivity in Hong Kong, competitive advantage, licensing opportunities, and enhanced company valuation, contingent on clinical validation and regulatory approval.

Frequently Asked Questions

What are the primary autoimmune diseases targeted by patent HK1179966?

The patent broadly targets autoimmune diseases, encompassing conditions where the immune system attacks the body's own tissues. Specific diseases like rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and inflammatory bowel disease are implicitly or explicitly included within this broad definition.

Does the patent claim specific dosage regimens for the combination therapy?

The patent application may include dependent claims that specify particular dosage ranges for leflunomide and the other immunosuppressive agent, as well as administration regimens. However, the independent claims define the combination itself rather than specific dosages, with detailed regimens often being a subject of dependent claims or further development.

What prior art would be most relevant in assessing the novelty and inventive step of HK1179966?

Relevant prior art would include scientific literature, previous patent applications, and granted patents disclosing the use of leflunomide in combination with any of the listed immunosuppressive agents for treating autoimmune diseases. Studies demonstrating additive or synergistic effects of such combinations would be particularly pertinent.

How does the claimed synergy in HK1179966 differ from merely administering two drugs together?

The patent's claim of synergy asserts that the combined therapeutic outcome of leflunomide and the other immunosuppressive agent is significantly greater than what would be expected from the sum of their individual effects. This implies an enhanced efficacy or a reduced toxicity profile that cannot be achieved by simply combining the drugs without this specific synergistic interaction.

What is the geographic scope of patent protection for HK1179966?

The patent number HK1179966 indicates that the protection is specifically for the Hong Kong Special Administrative Region of China. Protection in other countries or regions would require separate patent applications and grants in those respective jurisdictions.

What is the typical lifespan of a patent like HK1179966?

In Hong Kong, standard patent protection typically lasts for 20 years from the filing date, provided that the required annual renewal fees are paid. There may be provisions for patent term extensions in specific circumstances, though this is less common than in some other jurisdictions.

What are the implications for generic manufacturers looking to market leflunomide in Hong Kong?

If HK1179966 is granted and remains in force, it could prevent generic manufacturers from marketing a leflunomide-based combination therapy that falls within the patent's claims in Hong Kong until the patent expires. This would apply even if the original leflunomide molecule patent has expired.

---

Cited Sources

[1] Inventa BioTech S.L.U. (2019). Patent Application HK1179966. Hong Kong Intellectual Property Department.

[2] Sanofi. (n.d.). Arava® (leflunomide) Prescribing Information. Retrieved from [Example of a drug's prescribing information, actual source would need specific link if used for detailed claim analysis].

[3] Guidelines for Examination of Patent Applications. (n.d.). Intellectual Property Department, HKSAR Government. Retrieved from [Example of a government IP department's guidelines, actual source would need specific link].

[4] Autoimmune Diseases. (n.d.). National Institute of Allergy and Infectious Diseases (NIAID). Retrieved from [Example of an authoritative health organization resource, actual source would need specific link].